Get startedLog in
    Picture of HUTCHMED (China) logo

    13 — HUTCHMED (China) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Hutchmed (China) Announces NDA For Sovleplenib Accepted With Priority Review By NMPA

    Picture of HUTCHMED (China) logoHUTCHMED (China)
    29/04/2026 11:47
    April 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

NDA FOR SOVLEPLENIB IN WAHA ACCEPTED WITH PRIORITY REVIEW BY NMPA

PHASE TRIAL FOR SOVLEPLENIB IN WAHA MET PRIMARY ENDPOINT IN JANUARY 2026

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on HUTCHMED (China)

    See all news